Pharmaceutical equivalence and stability study of levofloxacin tablets commercialized in Europe and Africa

  1. Cáceres Pérez Amor R 1
  2. El Kory Mohamed B
  3. Elhadj Malick Kane
  4. Suárez Gonzalez Javier 1
  5. Betancor Inés
  6. Soriano Mabel
  7. Echezarreta Magdalena 1
  8. Santoveña Estevez Ana 1
  9. José B. Fariña Espinosa 1
  1. 1 Universidad de La Laguna
    info

    Universidad de La Laguna

    San Cristobal de La Laguna, España

    ROR https://ror.org/01r9z8p25

Actes:
XV Congreso de la Sociedad Española de Farmacia Industrial y Galénica
  1. I. Caraballo (ed. lit.)
  2. M.L. González-Rodríguez (ed. lit.)
  3. M. Casas (ed. lit.)
  4. A.M. Rabasco (ed. lit.)

Editorial: Sociedad Española de Farmacia Industrial y Galénica

ISBN: 978-84-09-35847-2

Any de publicació: 2021

Pàgines: 53-54

Congrés: XV Congreso de la Sociedad Española de Farmacia Industrial y Galénica

Tipus: Aportació congrés

Referències bibliogràfiques

  • [1] World Health Organization. Global Tuberculosis Report 2020. 2020.
  • [2] World Health Organization. A study on the public health and socioeconomic impact of substandard and falsified medical products. 2017.
  • [3] Kim HJ et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography–electrospray ionization–tandem mass spectrometry. J Pharm Biomed Anal. 2015;102:9-16. doi: 10.1016/j.jpba. 2014.08.026
  • [4] USP. Levofloxacin tablets. 2014.
  • [5] European Medicine Agency. Guideline on the investigation on the bioequivalence. 2010.